Back to top
more

Voyager Therapeutics (VYGR)

(Delayed Data from NSDQ)

$7.82 USD

7.82
495,064

+0.05 (0.64%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $7.80 -0.02 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VYGR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Voyager Therapeutics, Inc. [VYGR]

Reports for Purchase

Showing records 121 - 140 ( 142 total )

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 121

07/03/2017

Daily Note

Pages: 3

The Week Ahead in Life Sciences: Upcoming Events for the Week of July 3

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 122

05/10/2017

Company Report

Pages: 6

Q1 Financials; Cohort Three Data Ahead; Ph 3 Study On Track; Reiterate OUTPERFORM and $36 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 123

04/28/2017

Daily Note

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 1

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 124

04/21/2017

Industry Report

Pages: 6

The Week Ahead in Life Sciences: Upcoming Events for the Week of April 24

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 125

04/07/2017

Industry Report

Pages: 5

The Week Ahead in Life Sciences Upcoming Events for the Week of April 10.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 126

03/16/2017

Company Report

Pages: 6

Q4 Financials; On Track for Pivotal Study Initiation in Q4:17; Reiterate OUTPERFORM and $36 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 127

01/20/2017

Daily Note

Pages: 5

Coverage Data for Cohort 3 Reported; Topline Data on Track for Mid:17; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 128

12/08/2016

Company Report

Pages: 8

Large Improvements in Motor Function and Levodopa Response Validate VY-AADC01 Strategy in Advanced Parkinson''s Disease Patients; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 129

11/18/2016

Industry Report

Pages: 7

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 130

11/10/2016

Company Report

Pages: 7

Q3 Financials; VY-AADC01 Topline Readout for Two Cohorts in December, Additional Protocol Optimizations to Inform Pivotal Study

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 131

11/04/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 7

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 132

08/17/2016

Industry Report

Pages: 23

HEALTHCARE - 2016 PacGrow Healthcare Conference Day 1

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 133

08/17/2016

Industry Report

Pages: 23

Biotechnology/Biopharmaceuticals - 2016 PacGrow Healthcare Conference Day 1

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 134

08/11/2016

Company Report

Pages: 6

Q2 Results; VY-AADC01 Efficacy Data Ahead Could Provide Inflection Point, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 135

06/22/2016

Daily Note

Pages: 5

Coverage Data for Remaining Patients in Cohort 2 Above Threshold Likely Necessary for Clinical Efficacy, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 136

06/17/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences: Upcoming Events for the Week of June 20

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 137

06/10/2016

Daily Note

Pages: 6

The Week Ahead in Life Sciences: Upcoming Events for the Week of June 13

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 138

05/12/2016

Company Report

Pages: 5

Q1 EPS; Key Coverage Data Around the Corner, Reiterate OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 139

05/01/2016

Daily Note

Pages: 7

Lead Programs Highlighted; Two New Programs Announced

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Voyager Therapeutics, Inc.

Industry: Medical - Generic Drugs

Record: 140

03/17/2016

Company Report

Pages: 8

Q4 Financials; On Track for Key Updates and POC in Advanced Parkinson''s Disease in 2016; Reiterate OUTPERFORM and PT of $36

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party